The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
Open accessAbstract
Retinal gene therapy is increasingly recognized as a novel molecular intervention that has huge potential in treating common causes of blindness, the majority of which have a genetic aetiology1–5. Choroideremia is a chronic X-linked retinal degeneration that was first described in 18726. It leads to progressive blindness due to deficiency of Rab-escort protein 1 (REP1). We designed an adeno-associated viral vector to express REP1 and assessed it in a gene therapy clinical trial by subretinal injection in 14 patients with choroideremia. The primary endpoint was vision change in treated eyes 2 years after surgery compared to unoperated fellow eyes. Despite complications in two patients, visual acuity improved in the 14 treated eyes over controls (median 4.5 letter gain, versus 1.5 letter loss, P = 0.04), with 6 treated eyes gaining more than one line of vision (>5 letters). The results suggest that retinal gene therapy can sustain and improve visual acuity in a cohort of predominantly late-stage choroideremia patients in whom rapid visual acuity loss would ordinarily be predicted. The long-term follow-up results of a phase 1/2 retinal gene therapy clinical trial for choroideremia (NCT01461213) support the safety and efficacy of the treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“ocular AAV therapies leading to a permanent reduction in visual acuity following intraocular inflammation (9–11)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AAV dose-dependent intraocular inflammation and a few instances of persistent loss of visual acuity have been independently reported in clinical trials following subretinal AAV administration despite prophylactic immunosuppression (9–11).”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the perceived low immunogenicity of AAV and relative immune privilege of the intraocular environment,8 dose-dependent retinal inflammation, or gene therapy-associated uveitis (GTAU), has been observed in many retinal gene therapy trials, which limits the vector dose and therapeutic efficacy.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the phase 1/2 dose-escalation trials for RPE65-associated LCA, choroideremia, and retinitis pigmentosa GTPase regulator (RPGR)-associated X-linked retinitis pigmentosa, patients receiving higher doses of AAV have presented with various signs of retinal inflammation, including vitritis, retinitis, and choroiditis,2,6,7 implicating the presence of a cell-mediated immune response.”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the adoption of foot pedal-controlled viscous fluid injection systems has greatly improved injection pressure control during subretinal injection (Fischer et al., 2016; Xue et al., 2018).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Xue et al., 2018
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In contrast, subretinal gene therapy appears to induce NAb formation only infrequently in clinical trials and pre-clinical studies (Rakoczy et al., 2015; Reichel et al., 2018; Xue et al., 2018; Fischer et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Xue et al., 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [6]
In the citing paper
“Nonetheless, inflammatory reactions to gene therapy in the eye have led to permanent vision loss for some patients7–9.”
From Investigation of Cas9 Antibodies in the Human Eye (2022) · cites this paper as [9]
In the citing paper
“A phase I/II clinical trial of subretinal gene therapy using an AAV2 vector to deliver human REP1 to the outer retina has shown sustained preservation or improvement of visual acuity over 2 to 5 years in patients with advanced disease [MacLaren 2014, Xue 2018].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as Xue 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414264 · Cited by 1,651
MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62117-0 · Cited by 796
Self-citationRetinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337
Self-citationCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Clinical Characteristics and Current Therapies for Inherited Retinal DegenerationsPreprint
Sahel, J., Marazova, K., & Audo, I. S. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017111 · Cited by 249
Ghazi, N. G., Abboud, E. B., Nowilaty, S. R., Alkuraya, H., Alhommadi, A., Cai, H., Hou, R., Deng, W.-T., Boye, S. L., Almaghamsi, A., et al. (2016) · Human Genetics · doi:10.1007/s00439-016-1637-y · Cited by 243
Research works printed but not linked: 1
- Mauthner, L. Ein Fall von Choroideremia. Berl. Natur-med. Ver Innsbruck 2, 191 (1872).
Cited by
Sorted by citations
AAV cis -regulatory sequences are correlated with ocular toxicity
Xiong, W., Wu, D. M., Xue, Y., Wang, S. K., Chung, M. J., Ji, X., Rana, P., Zhao, S. R., Mai, S., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821000116 · Cited by 249
Bucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215
Garafalo, A. V., Cideciyan, A. V., Héon, E., Sheplock, R., Pearson, A., WeiYang Yu, C., Sumaroka, A., Aguirre, G. D., & Jacobson, S. G. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100827 · Cited by 173
Fundus-controlled perimetry (microperimetry): Application as outcome measure in clinical trials
Pfau, M., Jolly, J. K., Wu, Z., Denniss, J., Lad, E. M., Guymer, R. H., Fleckenstein, M., Holz, F. G., & Schmitz-Valckenberg, S. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100907 · Cited by 158
Self-citationSilva, S. R. D., Arno, G., Robson, A. G., Fakin, A., Pontikos, N., Mohamed, M. D., Bird, A. C., Moore, A. T., Michaelides, M., Webster, A. R., et al. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100898 · Cited by 154
Self-citationMembrane trafficking in health and disease
Yarwood, R., Hellicar, J., Woodman, P. G., & Lowe, M. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.043448 · Cited by 161
Storck, E. M., Morales‐Sanfrutos, J., Serwa, R. A., Panyain, N., Lanyon‐Hogg, T., Tolmachova, T., Ventimiglia, L. N., Martin‐Serrano, J., Seabra, M. C., Wójciak‐Stothard, B., et al. (2019) · Nature Chemistry · doi:10.1038/s41557-019-0237-6 · Cited by 121
Self-citationSingle-nuclei RNA-seq on human retinal tissue provides improved transcriptome profiling
Liang, Q., Dharmat, R., Owen, L. A., Shakoor, A., Li, Y., Kim, S., Vitale, A. T., Kim, I. K., Morgan, D. J., Liang, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12917-9 · Cited by 121
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
Zhou, M., Yu, Q., Huang, K., Mahov, S., Eslami, A., Maier, M. M., Lohmann, C. P., Navab, N., Zapp, D., Knoll, A., et al. (2019) · IEEE Transactions on Industrial Electronics · doi:10.1109/tie.2019.2937041 · Cited by 116
Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3278 · Cited by 92
Self-citationClinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 93
Bioengineering strategies for restoring vision
Cehajic-Kapetanovic, J., Singh, M. S., Zrenner, E., & MacLaren, R. E. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00836-4 · Cited by 79
Self-citationGene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 79
First-in-Human robot-assisted subretinal drug delivery under local anesthesia
Cehajic-Kapetanovic, J., Xue, K., Edwards, T. L., Meenink, T. C., Beelen, M. J., Naus, G. J., de Smet, M. D., & MacLaren, R. E. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.11.011 · Cited by 78
Self-citationThe Role of Müller Cells in Diabetic Macular Edema
Lai, D., Wu, Y., Shao, C., & Qiu, Q. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.10.8 · Cited by 80
Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration
Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L. (2019) · Retina · doi:10.1097/iae.0000000000002609 · Cited by 72
Self-citationXue, K., & MacLaren, R. E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1804853 · Cited by 70
Self-citationOptogenetic Gene Therapy for the Degenerate Retina: Recent Advances
McClements, M. E., Staurenghi, F., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.570909 · Cited by 73
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 73
Britten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Self-citationSuprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine
Khatib, T. Z., & Martin, K. R. G. (2019) · Current Eye Research · doi:10.1080/02713683.2019.1663385 · Cited by 61
Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
MacLaren, R. E., Fischer, M. D., Gow, J. A., Lam, B. L., Sankila, E.-M. K., Girach, A., Panda, S., Yoon, D., Zhao, G., & Pennesi, M. E. (2023) · Nature Medicine · doi:10.1038/s41591-023-02520-3 · Cited by 58
Self-citationDreismann, A. K., McClements, M. E., Barnard, A. R., Orhan, E., Hughes, J. P., Lachmann, P. J., & MacLaren, R. E. (2021) · Gene Therapy · doi:10.1038/s41434-021-00239-9 · Cited by 58
Self-citationChan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Advances in Vitreoretinal Surgery
Ribeiro, L. Z., Oliveira, J., Kuroiwa, D. A. K., Kolko, M., Brant, R., Junior, O., de Moraes, N. S. B., Vasconcelos, H., de Oliveira, T., & Maia, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216428 · Cited by 55
Has retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 55
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Self-citationChandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Self-citationTherapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Self-citationWang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 51
Orlans, H. O., McClements, M. E., Barnard, A. R., de la Cámara, C. M.-F., & MacLaren, R. E. (2021) · Nature Communications · doi:10.1038/s41467-021-25204-3 · Cited by 46
Self-citationCharacterizing the cellular immune response to subretinal AAV gene therapy in the murine retina
Chandler, L. C., McClements, M. E., Yusuf, I. H., Martinez-Fernandez de la Camara, C., MacLaren, R. E., & Xue, K. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.05.011 · Cited by 43
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.(6,7,40)”
BackgroundSelf-citationCurrent developments of gene therapy in human diseases
Liu, F., Li, R., Zhu, Z., Yang, Y., & Lu, F. (2024) · MedComm · doi:10.1002/mco2.645 · Cited by 43
Advances in ophthalmic optogenetics: approaches and applications
Prosseda, P. P., Tran, M., Kowal, T., Wang, B., & Sun, Y. (2022) · Biomolecules · doi:10.3390/biom12020269 · Cited by 41
Genome-editing strategies for treating human retinal degenerations
Quinn, J., Musa, A., Kantor, A., McClements, M. E., Cehajic-Kapetanovic, J., MacLaren, R. E., & Xue, K. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.231 · Cited by 41
Self-citationFocused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration
Fuller-Carter, P. I., Basiri, H., Harvey, A. R., & Carvalho, L. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00453-8 · Cited by 41
Adeno-Associated Virus Serotype 2–hCHM Subretinal Delivery to the Macula in Choroideremia
Alemán, T. S., Huckfeldt, R. M., Serrano, L. W., Pearson, D. J., Vergilio, G. K., McCague, S., Marshall, K. A., Ashtari, M., Doan, T. M., Weigel-DiFranco, C., et al. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2022.06.006 · Cited by 42
Retinal gene therapy: an eye-opener of the 21st century
Askou, A. L., Jakobsen, T. S., & Corydon, T. J. (2020) · Gene Therapy · doi:10.1038/s41434-020-0168-2 · Cited by 38
Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations
Talib, M., & Boon, C. J. F. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000290 · Cited by 37
Sobh, M., Lagali, P. S., Ghiasi, M., Montroy, J. R., Dollin, M. L., Hurley, B. R., Leonard, B. C., Dimopoulos, I. S., Lafreniere, M., Fergusson, D. A., et al. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.11.24 · Cited by 35
Wubben, T. J., Zacks, D. N., & Besirli, C. G. (2019) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000558 · Cited by 34
Sahel, J., Grieve, K. F., Pagot, C., Authié, C., Mohand‐Saïd, S., Pâques, M., Audo, I. S., Becker, K., Chaumet-Riffaud, A.-E., Azoulay-Sebban, L., et al. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.04.013 · Cited by 36
Ocular Inflammation and Treatment Emergent Adverse Events in Retinal Gene Therapy
Mehta, N., Robbins, D. A., & Yiu, G. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000366 · Cited by 33
Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases
Antas, P., Carvalho, C., Cabral-Teixeira, J., de Lemos, L., & Seabra, M. C. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.11.009 · Cited by 34
Self-citationUpdate on Clinical Trial Endpoints in Gene Therapy Trials for Inherited Retinal Diseases
Igoe, J., Lam, B. L., & Gregori, N. Z. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185512 · Cited by 33
CRISPR Interference–Potential Application in Retinal Disease
Peddle, C. F., Fry, L. E., McClements, M. E., & MacLaren, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072329 · Cited by 33
Self-citationShah, M., Shanks, M. E., Packham, E. R., Williams, J. P., Haysmoore, J., MacLaren, R. E., Nemeth, A. H., Clouston, P., & Downes, S. M. (2020) · Ophthalmic Genetics · doi:10.1080/13816810.2020.1778736 · Cited by 32
Self-citationNuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 31
Choroideremia: molecular mechanisms and therapies
Sarkar, H., & Moosajee, M. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.02.011 · Cited by 35
Shen, L. L., Ahluwalia, A., Sun, M., Young, B. K., Nardini, H. K. G., & Priore, L. V. D. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316028 · Cited by 30
Investigation of Cas9 Antibodies in the Human Eye
Toral, M. A., Charlesworth, C. T., Ng, B., Chemudupati, T., Homma, S., Nakauchi, H., Bassuk, A. G., Porteus, M. H., & Mahajan, V. B. (2022) · Nature Communications · doi:10.1038/s41467-022-28674-1 · Cited by 28
Shen, L. L., Ahluwalia, A., Sun, M., Young, B. K., Nardini, H. K. G., & Priore, L. V. D. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.03.003 · Cited by 27
McClements, M. E., Staurenghi, F., Visel, M., Flannery, J. G., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2021) · BioMed Research International · doi:10.1155/2021/4014797 · Cited by 27
Self-citationThe Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 27
Patient-Reported Health-Related Quality of Life in Individuals with Inherited Retinal Diseases
SCHOFIELD, D. J., Kraindler, J., Tan, O., Shrestha, R. N., Jelovic, D., West, S., Ma, A. S., Grigg, J., & Jamieson, R. V. (2021) · Ophthalmology Science · doi:10.1016/j.xops.2021.100106 · Cited by 28
Paavo, M., de Carvalho, J. R. L., Lee, W., Sengillo, J. D., Tsang, S. H., & Sparrow, J. R. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27366 · Cited by 25
Molecular Therapies for Choroideremia
Cehajic‐Kapetanovic, J., Barnard, A. R., & MacLaren, R. E. (2019) · Genes · doi:10.3390/genes10100738 · Cited by 25
Self-citationPatrício, M. I., Cox, C. I., Blue, C. E., Barnard, A. R., de la Cámara, C. M.-F., & MacLaren, R. E. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.005 · Cited by 25
Self-citationAccurate Quantification of AAV Vector Genomes by Quantitative PCR
de la Cámara, C. M.-F., McClements, M. E., & MacLaren, R. E. (2021) · Genes · doi:10.3390/genes12040601 · Cited by 26
Self-citationPurdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
Self-citationMorgan, J. I. W., Jiang, Y. Y., Vergilio, G. K., Serrano, L. W., Pearson, D. J., Bennett, J., Maguire, A. M., & Alemán, T. S. (2022) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2022.0158 · Cited by 24
Maierhofer, N. A., Jablonka, A.-M., Roodaki, H., Nasseri, M. A., Eslami, A., Klaas, J. E., Lohmann, C. P., Maier, M. M., & Zapp, D. (2023) · Journal of Robotic Surgery · doi:10.1007/s11701-023-01699-4 · Cited by 22
Update on Gene Therapy Clinical Trials for Choroideremia and Potential Experimental Therapies
Abbouda, A., Avogaro, F., Moosajee, M., & Vingolo, E. M. (2021) · Medicina · doi:10.3390/medicina57010064 · Cited by 22
Carvalho, C., Lemos, L., Antas, P., & Seabra, M. C. (2023) · Frontiers in Ophthalmology · doi:10.3389/fopht.2023.1270561 · Cited by 21
Self-citationSplit AAV8 Mediated ABCA4 Expression for Gene Therapy of Mouse Stargardt Disease (STGD1)
Li, R., Jing, Q., She, K., Wang, Q., Jin, X., Zhao, Q., Su, J., Song, L., Fu, J., Wu, X., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.017 · Cited by 21
Hints for gentle submacular injection in non-human primates based on intraoperative OCT guidance
Tan, G. S. W., Liu, Z., Ilmarinen, T., Barathi, V. A., Chee, C. K., Lingam, G., Su, X., & Stanzel, B. V. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.1.10 · Cited by 21
Progress in the development of novel therapies for choroideremia
Cehajic‐Kapetanovic, J., Patrício, M. I., & MacLaren, R. E. (2019) · Expert Review of Ophthalmology · doi:10.1080/17469899.2019.1699406 · Cited by 21
Self-citationKovacs, K. D., Ciulla, T. A., & Kiss, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2121646 · Cited by 20
MacDonald, I. M., Moen, C., Duncan, J. L., Tsang, S. H., Cehajic-Kapetanovic, J., & Aleman, T. S. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.17 · Cited by 20
Yusuf, I. H., McClements, M. E., MacLaren, R. E., & Issa, P. C. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108603 · Cited by 19
Self-citationParafoveal cone function in choroideremia assessed with adaptive optics optoretinography
Xu, P., Cooper, R. F., Jiang, Y. Y., & Morgan, J. I. W. (2024) · Scientific Reports · doi:10.1038/s41598-024-58059-x · Cited by 19
Ueno, S., Koyanagi, Y., Kominami, T., Ito, Y., Kawano, K., Nishiguchi, K. M., Rivolta, C., Nakazawa, T., Sonoda, K., & Terasaki, H. (2020) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-020-00752-1 · Cited by 19
CRISPR genome engineering for retinal diseases
Kantor, A., McClements, M. E., Peddle, C. F., Fry, L. E., Salman, A., Cehajic‐Kapetanovic, J., Xue, K., & MacLaren, R. E. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.024 · Cited by 19
Self-citationCRISPR Systems Suitable for Single AAV Vector Delivery
Stevanovic, M., Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Current Gene Therapy · doi:10.2174/1566523221666211006120355 · Cited by 19
Self-citationAssociation of Messenger RNA Level With Phenotype in Patients With Choroideremia
Fry, L. E., Patrício, M. I., Williams, J. P., Aylward, J. W., Hewitt, H., Clouston, P., Xue, K., Barnard, A. R., & MacLaren, R. E. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.5071 · Cited by 19
Self-citationMeasuring X-Chromosome inactivation skew for X-linked diseases with adaptive nanopore sequencingPreprint
Gocuk, S. A., Lancaster, J., Su, S., Jolly, J. K., Edwards, T. L., Hickey, D. G., Ritchie, M. E., Blewitt, M. E., Ayton, L. N., & Gouil, Q. A. (2024) · Genome Research · doi:10.1101/gr.279396.124 · Cited by 19
Self-citationMicroperimetry in Three Inherited Retinal Disorders
Bagdonaite-Bejarano, L., Hansen, R. M., & Fulton, A. B. (2019) · Seminars in Ophthalmology · doi:10.1080/08820538.2019.1622025 · Cited by 18
Hagag, A. M., Mitsios, A., Narayan, A. R., Abbouda, A., Webster, A. R., Dubis, A. M., & Moosajee, M. (2020) · Eye · doi:10.1038/s41433-020-0974-1 · Cited by 18
Self-citationStevanovic, M., Cehajic‐Kapetanovic, J., Jolly, J. K., & MacLaren, R. E. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14281 · Cited by 17
Self-citationNeedle detection and localisation for robot‐assisted subretinal injection using deep learning
Zhou, M., Guo, X., Grimm, M., Lochner, E., Jiang, Z., Eslami, A., Ye, J., Navab, N., Knoll, A., & Nasseri, M. A. (2023) · CAAI Transactions on Intelligence Technology · doi:10.1049/cit2.12242 · Cited by 17
MacLaren, R. E., Audo, I., Fischer, M. D., Huckfeldt, R. M., Lam, B. L., Pennesi, M. E., Sisk, R., Gow, J. A., Li, J., Zhu, K., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.017 · Cited by 15
Self-citationThe clinical safety landscape for ocular AAV gene therapies: A systematic review and meta-analysis
Liu, Z., Zhang, H., Jia, H., Wang, H., Huang, Z., Tang, Y., Wang, Z., Hu, J., Zhao, X., Li, T., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112265 · Cited by 15
Looking to the Future of Viral Vectors in Ocular Gene Therapy: Clinical Review
Kharisova, C. B., Kitaeva, K. V., Solovyeva, V. V., Sufianov, A. A., Суфианова, Г. З., Ахметшин, Р. Ф., Bulgar, S. N., & Rizvanov, A. A. (2025) · Biomedicines · doi:10.3390/biomedicines13020365 · Cited by 18
Inherited Retinal Disorders: Using Evidence as a Driver for Implementation
Sergouniotis, P. I. (2019) · Ophthalmologica · doi:10.1159/000500574 · Cited by 15
Gene Therapy for Inherited Retinal Disorders: Update on Clinical Trials
Michalakis, S., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Priglinger, C. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1384-0818 · Cited by 15
Low-contrast visual acuity versus low-luminance visual acuity in choroideremia
Wood, L. J., Jolly, J. K., Andrews, C. D., Wilson, I., Hickey, D. G., Cehajic‐Kapetanovic, J., & MacLaren, R. E. (2020) · Clinical and Experimental Optometry · doi:10.1111/cxo.13087 · Cited by 15
Self-citationTesting vision is not testing for vision
Peli, E. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.13.32 · Cited by 14
Choroideremia: The Endpoint Endgame
Elsayed, M. E. A. A., Taylor, L. J., Josan, A. S., Fischer, M. D., & MacLaren, R. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814354 · Cited by 14
Self-citationLi, J. D., Raynor, W., Dhalla, A.-H. Z., Viehland, C., Trout, R. M., Toth, C. A., Vajzovic, L. M., & Izatt, J. A. (2022) · Biomedical Optics Express · doi:10.1364/boe.483278 · Cited by 14
Choroideremia: Update On Clinical Features And Emerging Treatments
Brambati, M., Borrelli, E., Sacconi, R., Bandello, F. M., & Querques, G. (2019) · Clinical ophthalmology · doi:10.2147/opth.s195564 · Cited by 14
CHM mutation spectrum and disease: An update at the time of human therapeutic trials
Zeitz, C., Nassisi, M., Coriat, C., Andrieu, C., Boyard, F., Condroyer, C., Démontant, V., Antonio, A., Lancelot, M., Frederiksen, H. N., et al. (2021) · Human Mutation · doi:10.1002/humu.24174 · Cited by 14
Genetic therapies and potential therapeutic applications of CRISPR activators in the eye
Ng, B., Kaukonen, M. K., McClements, M. E., Shamsnajafabadi, H., MacLaren, R. E., & Cehajic‐Kapetanovic, J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101289 · Cited by 13
Self-citationZhai, Y., Xu, M., Radziwon, A., Dimopoulos, I. S., Crichton, P., Mah, R. A., MacLaren, R. E., Somani, R., TENNANT, M. T. S., & MacDonald, I. M. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.12.022 · Cited by 13
Self-citationPulman, J., Botto, C., Malki, H., Ren, D., Oudin, P., De Cian, A., As, M., Izabelle, C., Saubamea, B., Forster, V., et al. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102349 · Cited by 12
Expression of Rab Prenylation Pathway Genes and Relation to Disease Progression in Choroideremia
Fry, L. E., Patrício, M. I., Jolly, J. K., Xue, K., & MacLaren, R. E. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.8.12 · Cited by 12
Self-citationCehajic‐Kapetanovic, J., Bellini, M. P., Taylor, L. J., Yusuf, I. H., Soomro, T., da Cruz, L., & MacLaren, R. E. (2024) · Efficacy and Mechanism Evaluation · doi:10.3310/wara5730 · Cited by 11
Self-citationJolly, J. K., Nanda, A., Buckley, T. M. W., Pfau, M., Bridge, H., & MacLaren, R. E. (2023) · Translational Vision Science & Technology · doi:10.1167/tvst.12.2.10 · Cited by 11
Self-citation
Metadata
- Authors
- Xue, K., Jolly, J. K., Barnard, A. R., Rudenko, A., Salvetti, A. P., Patrício, M. I., Edwards, T. L., Groppe, M., Orlans, H. O., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., Downes, S. M., Seabra, M. C., & MacLaren, R. E.
- Affiliations
- University of Oxford (GB)
- Oxford University Hospitals NHS Trust (GB)
- Imperial College London (GB)
- St Mary's Hospital (GB)
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Southampton (GB)
- University College London (GB)
- Corresponding author
- MacLaren, Robert E.
- ORCID
- Venue
- Nature Medicine
- Published
- 2018-10
- Volume
- 24
- Issue
- 10
- Pages
- 1507-1512
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC7032956
- OpenAlex
- W2893026352
- Semantic Scholar
- c5ea88dabcecb2c7d2fa7f60b4ea7a8e431e29d4
- Cited by
- 185
- References
- 36
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 21 · 2023: 17 · 2022: 23 · 2021: 40 · 2020: 34 · 2019: 26 · 2018: 1
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (091984)
- National Institute for Health and Care Research (NF-SI-0515-10020, HICF-1009-006, NF-SI-0515-10047, CL-2014-13-003, ICA-CDRF-2016-02-002)
- Royal College of Surgeons of Edinburgh
- University College London
- University of Oxford
- Oxford University Hospitals NHS Foundation Trust
- Moorfields Eye Hospital NHS Foundation Trust
- Medical Research Council (MR/N00101X/1)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, Rab escort protein 1, REP1, adeno-associated virus vectors, subretinal injection, visual acuity, X-linked retinal degeneration, gene therapy clinical trials, visual outcome
- MeSH terms
- Dependovirus, Adult, Aged, Genetic Vectors, Humans, Male, Middle Aged, Retina, Retinal Degeneration, Vision, Ocular, Visual Acuity, Genetic Therapy, Choroideremia, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
